Stock Analysis
Sinphar PharmaceuticalLtd First Quarter 2024 Earnings: EPS: NT$0.66 (vs NT$0.48 in 1Q 2023)
Sinphar PharmaceuticalLtd (TWSE:1734) First Quarter 2024 Results
Key Financial Results
- Revenue: NT$777.4m (flat on 1Q 2023).
- Net income: NT$110.4m (up 38% from 1Q 2023).
- Profit margin: 14% (up from 10% in 1Q 2023).
- EPS: NT$0.66 (up from NT$0.48 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sinphar PharmaceuticalLtd shares are up 2.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Sinphar PharmaceuticalLtd you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Sinphar PharmaceuticalLtd is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:1734
Sinphar PharmaceuticalLtd
Researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan, Mainland China, the United States, Vietnam, and internationally.
Solid track record with excellent balance sheet.